SCHEDULE 13G/A: Douglas M. Singer Discloses 5.15% Stake in Interpace Biosciences, Inc.
Beneficial Ownership Disclosure
Douglas M. Singer has filed an amended Schedule 13G, reporting beneficial ownership of 5.15% of Interpace Biosciences, Inc.'s common stock as of December 31, 2024.
Summary
- Douglas M. Singer reported beneficial ownership of 227,046 shares of Interpace Biosciences, Inc. Common Stock.
- This ownership represents 5.15% of the total outstanding shares of the class.
- The filing indicates that Douglas M. Singer holds sole voting power and sole dispositive power over all 227,046 shares.
- The securities were not acquired or held for the purpose of changing or influencing the control of Interpace Biosciences, Inc., nor in connection with any transaction having such purpose or effect, other than activities solely in connection with a nomination under SEC rules.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing ownership, which is neutral in sentiment. The disclosure of a significant stake by an individual investor could be viewed positively by some, but the filing itself does not convey explicit positive or negative sentiment regarding the company's performance.
Positives
- The disclosure of a significant individual stake (5.15%) by Douglas M. Singer could be interpreted as a vote of confidence in Interpace Biosciences, Inc. by a substantial investor.
Negatives
- The document itself does not contain any negative information regarding the company's performance or outlook; it is purely a disclosure of ownership.
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This Schedule 13G filing is a standard regulatory disclosure of a significant ownership stake by an individual investor and does not provide broader industry context or trends.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant individual ownership stake in the company, which may influence perceptions of investor confidence or potential future shareholder activism.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement |
| 02/14/2025 | Date of signature and filing of the Schedule 13G Amendment No. 3 |
Keywords
INTERPACE BIOSCIENCES, Douglas M. Singer, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Shareholder Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.